Drug Insights

Unveiling Acyclovir: How to Search for it on Synapse

27 February 2024
2 min read

Acyclovir is a synthetic purine nucleoside analogue,tradename as ZOVIRAX .Acyclovir has in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV).The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In vitro, acyclovir triphosphate stops replication of herpes viral DNA. ZOVIRAX (acyclovir) is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients. Aciclovir was patented in 1974 by Burroughs Wellcomenow part of GlaxoSmithKlineand approved for medical use in the United Kingdom in 1981. Click on the image below to begin the exploration journey of Acyclovir through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Voyager's Gene Therapy Shows Promise in Early Alzheimer's Trial, Advances to Later Phase
Latest Hotspot
3 min read
Voyager's Gene Therapy Shows Promise in Early Alzheimer's Trial, Advances to Later Phase
27 February 2024
Voyager Therapeutics Announces Promising Early-Stage Results for Gene Therapy Aimed at Attenuating Tau in Alzheimer's, Pushes Project into Later Research Phase.
Read →
Decoding Darolutamide: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
Decoding Darolutamide: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
27 February 2024
Hospitalization data for darolutamide/docetaxel in metastatic prostate cancer were presented at 2024 ASCO_GU on Jan 25, comparing daro/docetaxel/ADT with placebo/docetaxel/ADT.
Read →
Immune-Onc Therapeutics Announces Partnership for International Early-Stage Trial of IO-108 as First-Line Treatment for Advanced Liver Cancer
Latest Hotspot
3 min read
Immune-Onc Therapeutics Announces Partnership for International Early-Stage Trial of IO-108 as First-Line Treatment for Advanced Liver Cancer
27 February 2024
Immune-Onc Therapeutics Discloses a Partnership for Clinical Research, Assessing IO-108 in an International Early Phase Trial Aimed at Initial Therapy for Progressive Hepatic Carcinoma.
Read →
Expert Tips for Searching Celecoxib on Synapse
Drug Insights
2 min read
Expert Tips for Searching Celecoxib on Synapse
27 February 2024
CELEBREX (celecoxib) is a nonsteroidal anti-inflammatory drug. Celecoxib has analgesic, anti-inflammatory, and antipyretic properties.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.